Clinical trials: Mild Asthma
Healthy Volunteer Study, Healthy Adults
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma.
- Conditions
- Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma
- Trial name
- NCT07660731
- Testing
- PF-08103402, Midazolam
- Where
- 2 sites in United States, Belgium
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma
Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma
The purpose of this study is to evaluate the effect of IMA-026, an antibody to IL-13, on airway hyperresponsiveness and airway inflammation in mild asthmatics.
- Trial name
- NCT00725582
- Testing
- IMA-026
- Volunteers
- 24 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Asthma
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will assess the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist (SABA)…
- Trial name
- NCT02104674
- Testing
- Lebrikizumab, Montelukast
- Where
- 82 sites in United States, Brazil and 9 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
Asthma
Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Primary purpose of the protocol is to determine if IMA-638 prevents a mild asthma attack by a subject with mild asthma inhaling an allergen.
- Trial name
- NCT00410280
- Testing
- IMA-638 is a biologic
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Pfizer
Asthma
Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma
This study will investigate the safety and tolerability of indacaterol maleate/mometasone furoate via the Twisthaler device after 14 days treatment in patients with mild to moderate asthma.
- Trial name
- NCT00605306
- Testing
- indacaterol maleate / mometasone furoate
- Where
- 3 sites in France
- Volunteers
- 28 people
- Sponsor
- Novartis
Asthma
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma
The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo…
- Trial name
- NCT00393991
- Testing
- Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10
- Where
- 57 sites in United States, Canada
- Volunteers
- 475 people
- Sponsor
- SkyePharma AG
Asthma
Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge
The study will investigate the effect of treatment with RNS60 for 21 days. Subjects' FEV1 will be measured after an inhaled allergen challenge at baseline and again after 21 days of treatment.
- Trial name
- NCT02422121
- Testing
- RNS60
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Revalesio Corporation
Allergic Asthma
A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
This is a multicenter, randomized, double-blind, placebo-controlled study designed to demonstrate the safety and efficacy of MILR1444A compared with placebo in reducing the airway reaction to an inhaled aeroallergen solution in…
- Trial name
- NCT00781443
- Testing
- lebrikizumab (MILR1444A)
- Volunteers
- 29 people
- Sponsor
- Genentech, Inc.
Asthma
A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety, and tolerability of huMAb OX40L administered to patients by IV infusion for the treatment of…
- Trial name
- NCT00983658
- Testing
- huMAb OX40L
- Volunteers
- 29 people
- Sponsor
- Genentech, Inc.
Asthma
Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142)
The aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function, time to first asthma exacerbation, asthma symptoms, use of rescue medication, and quality of life in patients with…
- Trial name
- NCT00163423
- Testing
- Ciclesonide
- Where
- 51 sites in Austria, Canada and 3 more
- Volunteers
- 480 people
- Sponsor
- AstraZeneca
Asthma
Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium MDI (PT001)…
- Trial name
- NCT02433834
- Testing
- Glycopyrronium MDI, Serevent Diskus 50 μg
- Where
- 43 sites in United States
- Volunteers
- 248 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma
Study in Mild Asthmatic Patients
The purpose of this study is to determine the safety and usefulness of GSK2190915 in asthmatic patients who develop asthma symptoms following being challenged.
- Trial name
- NCT00748306
- Testing
- GSK2190915 - 100mcg
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Asthma
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma
Approximately 480 (120 per group) would need to complete the 12 weeks of treatments.
- Trial name
- NCT03835871
- Testing
- 400 µg per day Beclomethasone, 200 µg per day Beclomethasone, 100 µg per day Beclomethasone
- Sponsor
- Adamis Pharmaceuticals Corporation
Asthma
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
- Trial name
- SITAR (NCT01591044)
- Testing
- R940343 1mg, R940343 2mg
- Where
- 59 sites in United States, Canada
- Volunteers
- 301 people
- Sponsor
- Rigel Pharmaceuticals
Mild to Moderate Asthma
Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma
The primary purpose of this study is to evaluate the early bronchodilating effect of SKP FlutiForm HFA pMDI compared to placebo.
- Trial name
- NCT00734292
- Testing
- fluticasone propionate, formoterol fumarate
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- SkyePharma AG
Safety and Tolerability
PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
This will be a randomized, open-label, active-controlled, single dose crossover study with either three or four treatment periods.
- Trial name
- NCT03307512
- Testing
- inhaled human insulin, Insulin Lispro (Humalog U-100)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dance Biopharm Inc.
Asthma
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
- Trial name
- NCT07241546
- Testing
- ARO-RAGE
- Where
- 6 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Arrowhead Pharmaceuticals
Atopic Asthma
A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma
This is the first study in human patients with asthma that the sponsor is conducting in order to evaluate if there are signals that the investigational medication, AXP1275, may be a safe and effective treatment for asthma.
- Trial name
- NCT01890161
- Testing
- AXP1275
- Where
- 3 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Axikin Pharmaceuticals, Inc.
Asthma
A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma
This is a Phase IIa, multicentre, single dose, randomised, double blind, controlled, 2 way cross-over study to evaluate the potential for bronchoconstriction of the new HFA-152a propellant (single dose) versus the marketed…
- Trial name
- NCT05472662
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects
The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) administered pre-dose versus post-dose, while receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice…
- Trial name
- NCT00449501
- Testing
- Budesonide/formoterol pMDI, Budesonide HFA pMDI
- Where
- 46 sites in United States
- Volunteers
- 134 people
- Sponsor
- AstraZeneca